Chesapeake Clinical Research — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$4,250	1
2024	Research	$15,561	5
2023	Research	$46,579	16
2022	Research	$108,942	7
2021	Research	$121,503	8
2020	Research	$79,967	8
2019	Research	$41,550	16

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $293,277 22 payments
GlaxoSmithKline, LLC. $62,953 7 payments
Teva Pharmaceuticals USA, Inc. $46,901 15 payments
Octapharma USA, Inc. $10,387 3 payments
Eli Lilly and Company $4,250 1 payment
Cipla USA Inc. $585 13 payments

Studies the money was for Research payments · program years 2019–2025

A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study to Assess the Efficacy and Safety of Csj117, When Added to Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. $119,068 3 payments
A Randomised Phiii Study to Assess the Effect of 100 MG SC Mepolizumab $62,953 7 payments
Study to Evaluate the Efficacy, Safety, Tolerability, and Immunogenicity of TEV-45779 Compared to XOLAIR (Omalizumab) in Patients With Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine (H1) Treatment $43,831 13 payments
A Multi Center Randomized Double Blind Active and Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihis $28,876 2 payments
A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy $28,852 3 payments
A 24-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Extension Study to Assess the Safety of Csj117, When Added to Existing Standard of Care Asthma Therapy in Patients ?18 Years of Age $24,973 2 payments
A Multi Center Randomized Double Blind Active and Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihistamines $22,871 1 payment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (Lou064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (Csu) Patients Inadequately Controlled By H1-Antihi $22,615 1 payment
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of Ligelizumab (Qge031) in the Treatment of Chronic Inducible Urticaria (Cindu) in Adolescents and Adults Inadequately Controlled By H1-Antihistamines $14,743 3 payments
A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Study of Fevipiprant Once Daily Plus Standard of Care Soc for Assessment of the Efficacy in Reduction of Nasal Polyps Size in Patients With Nasal Polyposis and Concomitant Asthma $12,666 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.